Core Viewpoint - 百心安-B's stock price increased by nearly 12% following the announcement of the registration of its Iberis RDN system in New Zealand, highlighting positive market sentiment towards the company's advancements in medical technology [1] Company Developments - 百心安-B's subsidiary, Shanghai Antong Medical Technology Co., Ltd., has successfully registered the Iberis RDN system with New Zealand's Medsafe [1] - The Iberis RDN system is the only renal denervation (RDN) product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods, enhancing safety, efficacy, and cost-effectiveness of RDN procedures [1] - The ultimate goal of the company is to provide outpatient RDN surgeries for patients worldwide [1] Market Performance - As of the report, 百心安-B's stock was trading at 6.85 HKD with a trading volume of 430.19 million HKD, reflecting strong investor interest [1]

Core Viewpoint - The stock of Baixinan-B (02185) surged nearly 12% following the announcement of the registration of its Iberis RDN system in New Zealand, marking a significant milestone for the company in the renal denervation market [1] Group 1: Company Developments - Baixinan-B's subsidiary, Shanghai Antong Medical Technology Co., Ltd., has successfully registered the Iberis RDN system with New Zealand's Medsafe [1] - The Iberis RDN system is the only renal denervation product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1] - The TRA method enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [1] Group 2: Market Position and Goals - The company's ultimate goal is to provide outpatient renal denervation surgeries to patients worldwide [1] - The Iberis RDN system received CE marking in Europe in 2016, indicating its established presence in the international market [1]

Core Insights - The company Baixinan-B (02185) announced that its subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), has successfully registered the Iberis Renal Denervation (RDN) system with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) [1] - Antong has formed a strategic partnership with Bosheng International Group Ltd. (Bosheng) for the commercialization of the Iberis RDN system across multiple regions, including the EU, Asia-Pacific, and Latin America [1] - The Iberis RDN system is currently the only RDN product globally approved for both transradial access (TRA) and transfemoral access (TFA), enhancing safety, efficacy, and cost-effectiveness of the procedure [1] Company Overview - Bosheng is a company registered in Bermuda and is a subsidiary of Shenzhen Stock Exchange-listed Blue Sail Medical Co., Ltd. (stock code: 002382), focusing on cardiovascular business [2] - Bosheng operates globally with its headquarters in Singapore and European headquarters in Morges, Switzerland, aiming to meet healthcare needs through a combination of direct sales and a global distribution network [2] - The company is committed to supporting medical education and advancing patient care by organizing training courses, scientific summits, and related activities at international and national levels [2]